⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Join Class Action to Recover Losses from Regeneron Pharmaceuticals, Inc. (REGN) - Contact Levi & Korsinsky Before September 14, 2026
accessnewswire.com
REGN
Securities Lawsuit Alert: Regeneron Pharmaceuticals, Inc. (REGN) – Contact Levi & Korsinsky Before September 14, 2026
accessnewswire.com
REGN
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS
prnewswire.com
REGN
Securities Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - Levi & Korsinsky Represents Shareholders
accessnewswire.com
REGN
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
businesswire.com
REGN
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
businesswire.com
REGN
Securities Fraud Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - Levi & Korsinsky Reminds Investors of September 14, 2026
accessnewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
globenewswire.com
REGN
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE
Contact Levi & Korsinsky by September 14, 2026 to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)
accessnewswire.com
REGN